Powder: -20°C for 3 years | In solvent: -80°C for 1 year
NVX-207 is a derivative of betulinic acid. It has anti-cancer activity.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | 6-8 weeks | $ 523.00 | |
25 mg | 6-8 weeks | $ 1,520.00 | |
50 mg | 6-8 weeks | $ 1,980.00 | |
100 mg | 6-8 weeks | $ 2,500.00 |
Description | NVX-207 is a derivative of betulinic acid. It has anti-cancer activity. |
In vitro | NVX-207 decreases cell death via apoptosis. NVX-207 has high cytotoxicity (IC50: ranging from 7.6-8.5 μM), in the three analyzed malignant glioma cell lines. NVX-207 leads to PARP cleavage and to a decrease in Survivin expression levels under normoxic and hypoxic conditions. NVX-207 displays anti-tumor activity (mean IC50 = 3.5 μM) against various human and canine cell lines. NVX-207-induced apoptosis is associated with activation of the intrinsic apoptotic pathway via cleavage of caspases -9, -3, -7, and of poly (ADP-ribose) polymerase (PARP). NVX-207 (20 μM) induces a significantly high rate of necrosis of glioma cell lines[1][2]. |
In vivo | The intravenous application of NVX-207 is well tolerated in mice[1]. |
Molecular Weight | 601.86 |
Formula | C36H59NO6 |
CAS No. | 745020-66-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 125 mg/mL (207.69 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
NVX-207 745020-66-0 Others NVX207 NVX 207 inhibitor inhibit